BRIEF—Taltz clocks up second EU approval

US pharma major Eli Lilly has added a second European approval for Taltz (ixekizumab).

The European Commission has granted marketing authorization for its use alone or in combination with methotrexate, for the treatment of active psoriatic arthritis (PsA) in adults who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drug therapies.

This adds to the European approval, granted in April 2016, of Taltz for moderate-to- severe plaque psoriasis in adults who are candidates for systemic therapy.

PsA affects up to 30% of people who are already living with psoriasis and causes serious joint pain and swelling.